4-Chloro-3-ethylbenzaldehyde → HCID 86685274, Verbindung

HRID 402820

Reaktionsgleichung

Reaktionsgleichung von HRID 402820
Cl.[O:2]=[C:3]1[N:7]([C:8]2[CH:16]=[CH:15][C:11]([C:12]([OH:14])=[O:13])=[CH:10][CH:9]=2)[CH2:6][C:5]2([CH2:21][CH2:20][NH:19][CH2:18][CH2:17]2)[O:4]1.[Cl:22][C:23]1[CH:30]=[CH:29][C:26]([CH:27]=O)=[CH:25][C:24]=1[CH2:31][CH3:32]>>[Cl:22][C:23]1[CH:30]=[CH:29][C:26]([CH2:27][N:19]2[CH2:18][CH2:17][C:5]3([O:4][C:3](=[O:2])[N:7]([C:8]4[CH:9]=[CH:10][C:11]([C:12]([OH:14])=[O:13])=[CH:15][CH:16]=4)[CH2:6]3)[CH2:21][CH2:20]2)=[CH:25][C:24]=1[CH2:31][CH3:32]

Komponenten

3

Edukt 2

HCID 552650954-Chloro-3-ethylbenzaldehydeHCID 667646964-{2-Oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-ylbenzoic acid hydrochloride

Produkt 1

HCID 86685274HCID 86685274, VerbindungAusbeute 43,7 %

Versuchsvorschrift

The title compound was prepared from 4-(2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-3-yl)benzoic acid hydrochloride salt (20 mg, 0.064 mmol; Example 5-1, Step 4) and 4-chloro-3-ethylbenzaldehyde (11.86 mg, 0.070 mmol), following essentially the same procedure described in Example 7-1. The residue was purified by reverse phase (C-18) HPLC eluting with acetonitrile/water+0.1% NH3. The solvent was evaporated to provide the title compound as a white solid (12 mg).

Aufarbeitung

  1. customThe residue was purified by reverse phase (C-18) HPLC
  2. washeluting with acetonitrile/water+0.1% NH3
  3. customThe solvent was evaporated

Quellen und Nachweise

ORD-Eintrag
ord-2d755abae5d440d5b273911850973d66
Quelldatensatz
uspto-grants-2014_06
Patentnummer
US08742110B2

Verknüpfte Notizen

Wird geladen…